Some benefits depend on glucosuria or the interaction between the SGLT2 inhibitor drug and the SGLT2 transporter.14,22,23 Increased glucosuria promotes a glucose deficit, lowers glucose and insulin in circulation, disinhibits lipolysis, increases circulating free fatty acids (FFAs) and ketone bodies, and promotes a switch in substrate utilization.22 Selective inhibition of SGLT2-mediated glucose and sodium reabsorption in the proximal tubule of the kidneys, leads to the complement of glucosuria, natriuresis, and osmotic diuresis. The gene discussed is SLC5A2; the disease is Glycosuria.